Total Funding
56
73
Total FundingPost-IPO Debt raised
Growth Score
-12 pts
Heat Score
-18 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
11042
Allarity Therapeutics is a biopharma company developing oncology products and drugs for the personalized treatment of cancer.
- James G. Cullem: Interim Chief Executive OfficerPast Role: Allarity Therapeutics, Chief Business Officer
Steen Knudsen: Chief Science Officer & FounderPast Role: Medical Prognosis Institute, Chief Science Officer
About the Company
Allarity Therapeutics is a biopharmaceutical company that develops oncology products and drugs for the personalized treatment of cancer. The company utilizes drug response predictor technology to refine patient selection and improve clinical outcomes. Its product pipeline includes Dovitinib, a pan-tyrosine kinase inhibitor for renal cell carcinoma
(RCC), Stenoparib (2X-121), a dual PARP inhibitor, and Tankyrase Inhibitor for ovarian cancer; IXEMPRA (Ixabepilone), a microtubulin inhibitor for metastatic breast cancer.
